Overview

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

Status:
Completed

Trial end date:
2017-06-22

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.

Phase:

Phase 2

Details

Lead Sponsor:

Tobira Therapeutics, Inc.

Treatments:

Cenicriviroc
TAK-652